

# AWMSG ADVICE SUPERSEDED BY AWMSG REVIEW

## Provision of pre-exposure prophylaxis (PrEP) for HIV prevention in Wales April 2020

### Final Appraisal Recommendation

Advice No: 0817 – April 2017

**Emtricitabine/tenofovir disoproxil (as fumarate) (Truvada®)  
200 mg/245 mg film-coated tablets**

**Submission by Gilead Sciences Ltd**

### Recommendation of AWMSG

**Emtricitabine/tenofovir disoproxil fumarate (Truvada®) is not recommended for use within NHS Wales in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.**

**The case for cost-effectiveness has not been proven.**

#### Key factor(s) influencing the recommendation:

- There are several uncertainties and limitations in the economic model provided in the company's submission.

#### Additional note(s):

- Patients who are currently being treated with emtricitabine/tenofovir disoproxil fumarate (Truvada®) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.
- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1625), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0817:  
Emtricitabine/tenofovir disoproxil (as fumarate) (Truvada®) 200 mg/245 mg film-coated tablets.  
April 2017.